Company Press Release
SOURCE: Cephalon, Inc.
Cephalon and Lundbeck Initiate Clinical Program With CEP-1347 for
Neurodegenerative Diseases
http://biz.yahoo.com/prnews/990722/pa_cephalo_1.html
WEST CHESTER, Pa., July 22, 1999 /PRNewswire/ -- Cephalon, Inc. (Nasdaq:
CEPH - news) announced today that, in collaboration with H. Lundbeck A/S
(CSE: LUN - news), the first trial has begun in the companies' clinical
program to evaluate the safety and tolerability of CEP-1347, Cephalon's
orally active small molecule, for the treatment of neurodegenerative
diseases, specifically Parkinson's disease and Alzheimer's disease.
In neurodegenerative diseases, the underlying pathology is a profound and
irreplaceable neuronal death. Such neuronal loss is critically influenced by
activation of the stress-activated protein (SAP) kinase pathway. CEP-1347
selectively and potently inhibits key kinases within the SAP kinase pathway,
thereby blocking cell death in neurons. In preclinical models of
neurodegenerative diseases, CEP-1347 enhances neuronal survival and supports
normal neurological function.
The study announced today is a single, rising dose, placebo-controlled,
Phase 1 study, designed to evaluate the safety, tolerability and
pharmacokinetics of CEP-1347. The study is being conducted in healthy young
and elderly male volunteers.<SNIP>
NOTE: Cephalon's press releases are posted on the Internet at the company's
Web site at http://www.cephalon.com. They are also available by fax 24 hours
a day at no charge by calling PR Newswire's Company News On-Call at
800-758-5804, extension 134563.
SOURCE: Cephalon, Inc.
Copyright © 1999 PRNewswire.
--
Judith Richards, London, Ontario, Canada
[log in to unmask]
^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
```````
